Last updated: August 17, 2026

Application No. 17/604,375

EXOSOME MIMICKING NANOVESICLES MAKING AND BIOLOGICAL USE

Final Rejection

Filed

Oct 15, 2021

Priority

Apr 18, 2019 — provisional 62/836,028 +1 more

Examiner

ZARA, JANE J

Art Unit

1637

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

The Regents of the University of California

OA Round

3 (Final)

Interview Optional

— +16.1% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 71% grant rate with +16.1% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 1100 resolved cases, 2023–2026

Examiner Intelligence

ZARA, JANE J View full profile →

Grants 71% — above average

Career Allowance Rate

780 granted / 1100 resolved

+10.9% vs TC avg

Strong +16% interview lift

Without

With

+16.1%

Interview Lift

resolved cases with interview

Typical timeline

2y 10m

Avg Prosecution

46 currently pending

Career history

1141

Total Applications

across all art units

Statute-Specific Performance

§101

5.4%

-34.6% vs TC avg

§103

30.7%

-9.3% vs TC avg

§102

15.2%

-24.8% vs TC avg

§112

32.9%

-7.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1100 resolved cases

Prosecution Timeline

Show 1 earlier event

Aug 01, 2025

Non-Final Rejection mailed

Jan 30, 2026

Response after Non-Final Action

Jan 30, 2026

Response Filed

Feb 24, 2026

Final Rejection mailed

Jun 02, 2026

Applicant Interview (Telephonic)

Jun 03, 2026

Examiner Interview Summary

Jun 23, 2026

Response after Non-Final Action

Jul 16, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/506,070

Patent 12703734

METHOD OF ASSESSING ACTIVITY OF RECOMBINANT ANTIGEN RECEPTORS

2y 9m to grant Granted Aug 11, 2026

17/907,826

Patent 12698501

USP10 TARGETED SELF-DELIVERABLE SIRNA COMPOSITIONS AND METHODS FOR PREVENTING OR INHIBITING FIBROSIS AND/OR SCARRING

3y 11m to grant Granted Aug 04, 2026

17/751,152

Patent 12692547

METHODS OF TREATING CANCERS CONTAINING FUSION GENES

4y 2m to grant Granted Jul 28, 2026

18/446,929

Patent 12692498

MODIFIED OLIGONUCLEOTIDES TARGETING SNPs

2y 11m to grant Granted Jul 28, 2026

17/836,020

Patent 12655430

HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

4y 0m to grant Granted Jun 16, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5

Expected OA Rounds

71%

Grant Probability

87%

With Interview (+16.1%)

2y 10m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 1100 resolved cases by this examiner. Grant probability derived from career allowance rate.